Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18759723 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | June 2024 | December 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18749504 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | June 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18749522 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | June 2024 | March 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18393153 | METHODS FOR MODULATING AN IMMUNE RESPONSE | December 2023 | December 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18227057 | METHODS FOR MODULATING AN IMMUNE RESPONSE | July 2023 | January 2024 | Allow | 6 | 2 | 1 | No | No |
| 18143978 | DOSING PARAMETERS FOR CD47 TARGETING THERAPIES TO HEMATOLOGIC MALIGNANCIES | May 2023 | November 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18177729 | ANTI-CD39 ANTIBODIES AND USE THEREOF | March 2023 | March 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18154998 | SITE-SPECIFIC ANTIBODY CONJUGATION AND ANTIBODY-DRUG CONJUGATE AS SPECIFIC EMBODIMENT THEREOF | January 2023 | December 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 18069712 | ANTI-C3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES | December 2022 | August 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18048644 | FACTOR XI A2 DOMAIN-BINDING ANTIBODIES AND METHODS OF USE THEREOF | October 2022 | January 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18047243 | COMBINATION THERAPY USING A LIV1-ADC AND A CHEMOTHERAPEUTIC | October 2022 | April 2025 | Abandon | 30 | 0 | 1 | No | No |
| 17961001 | METHODS FOR MODULATING AN IMMUNE RESPONSE | October 2022 | June 2023 | Allow | 8 | 1 | 1 | No | No |
| 17938317 | TCR COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING | October 2022 | December 2023 | Abandon | 15 | 1 | 0 | Yes | No |
| 17933193 | RECOMBINANT POLYPEPTIDES FOR MEMBRANE FUSION AND USES THEREOF | September 2022 | July 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17818838 | COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT | August 2022 | June 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17852419 | NKp46 BINDING AGENTS | June 2022 | March 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 17834709 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | June 2022 | January 2023 | Allow | 7 | 1 | 0 | No | No |
| 17805121 | MULTISPECIFIC ANTAGONISTS | June 2022 | July 2023 | Abandon | 13 | 1 | 0 | Yes | No |
| 17752631 | METHODS OF CONJUGATING AN AGENT TO A THIOL MOIETY IN A PROTEIN THAT CONTAINS AT LEAST ONE TRISULFIDE BOND | May 2022 | June 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17736874 | MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS | May 2022 | June 2023 | Allow | 13 | 3 | 0 | No | No |
| 17736847 | MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS | May 2022 | June 2023 | Allow | 13 | 3 | 0 | Yes | No |
| 17736222 | TREATMENT USING CHIMERIC RECEPTOR T CELLS INCORPORATING OPTIMIZED POLYFUNCTIONAL T CELLS | May 2022 | February 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17735880 | PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY | May 2022 | March 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17733260 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | April 2022 | January 2023 | Allow | 9 | 1 | 0 | No | No |
| 17728671 | CANCER VACCINES TARGETING LEMD1 AND USES THEREOF | April 2022 | February 2025 | Allow | 34 | 1 | 1 | Yes | No |
| 17728704 | Cancer Vaccines Targeting PRAME and Uses Thereof | April 2022 | April 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17725932 | IDENTIFICATION OF IMMUNOLOGICALLY PROTECTIVE NEO-EPITOPES FOR THE TREATMENT OF CANCERS | April 2022 | March 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17718822 | METHODS OF TREATING INFLAMMATORY DISORDERS WITH MULTIVALENT FC COMPOUNDS | April 2022 | February 2025 | Allow | 34 | 1 | 0 | No | No |
| 17709324 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | March 2022 | October 2023 | Abandon | 18 | 3 | 0 | Yes | No |
| 17707838 | ENDOSIALIN-BINDING ANTIBODY | March 2022 | December 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17586177 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND IMMUNE CHECKPOINT INHIBITOR | January 2022 | February 2025 | Allow | 36 | 1 | 1 | No | No |
| 17648792 | HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF | January 2022 | March 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17582160 | CHIMERIC PROTEINS FOR TARGETING dsRNA | January 2022 | November 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17575616 | METHODS OF CANCER TREATMENT USING ACTIVATED T CELLS | January 2022 | January 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17570917 | METHODS AND COMPOSITIONS FOR T CELL THERAPY | January 2022 | April 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17567923 | EARLY APOPTOTIC CELLS FOR USE TREATING SEPSIS | January 2022 | January 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17563162 | Pharmaceutical Composition for Treating Tumor | December 2021 | September 2022 | Allow | 9 | 3 | 1 | Yes | No |
| 17559824 | CANCER VACCINES TARGETING MUC16 AND USES THEREOF | December 2021 | December 2024 | Allow | 36 | 1 | 1 | No | No |
| 17558430 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | December 2021 | July 2023 | Allow | 19 | 3 | 1 | Yes | No |
| 17553624 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | December 2021 | January 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17540672 | COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS | December 2021 | October 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17532332 | CANCER ANTIGEN TARGETS AND USES THEREOF | November 2021 | February 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17529566 | METHOD FOR OBTAINING GLOBALLY ACTIVATED MONOCYTES | November 2021 | March 2025 | Allow | 40 | 1 | 1 | No | No |
| 17527835 | MOLECULAR SIGNATURE OF CANCER | November 2021 | May 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17508474 | METHODS TO PRESERVE TUMOR-STROMAL INTERACTIONS IN CULTURE AND THERAPEUTIC PREDICTIVE APPLICATIONS THEREOF | October 2021 | March 2025 | Allow | 41 | 3 | 1 | Yes | No |
| 17500874 | POOLED NK CELLS FROM UMBILICAL CORD BLOOD ASSOCIATED WITH ANTIBODIES AND THEIR USES FOR THE TREATMENT OF DISEASE | October 2021 | December 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17492219 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | October 2021 | December 2021 | Allow | 2 | 0 | 0 | No | No |
| 17491742 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | October 2021 | April 2024 | Allow | 30 | 1 | 1 | No | No |
| 17484703 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | September 2021 | November 2021 | Allow | 2 | 0 | 0 | No | No |
| 17484568 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | September 2021 | November 2024 | Abandon | 38 | 2 | 1 | Yes | No |
| 17482708 | NOVEL BISPECIFIC POLYPEPTIDES AGAINST CD137 | September 2021 | August 2024 | Allow | 35 | 1 | 2 | Yes | No |
| 17479142 | CANCER VACCINES TARGETING BORIS AND USES THEREOF | September 2021 | August 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17471803 | METHODS AND MATERIALS FOR ASSESSING IMMUNE SYSTEM PROFILES | September 2021 | August 2024 | Allow | 35 | 1 | 0 | No | No |
| 17469488 | ANTI-CD40 ANTIBODIES AND USES THEREOF | September 2021 | July 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17467728 | CANCER VACCINES TARGETING MESOTHELIN AND USES THEREOF | September 2021 | January 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17468265 | Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies | September 2021 | December 2024 | Allow | 39 | 3 | 1 | Yes | No |
| 17459460 | METHODS OF TREATING CERVICAL CANCER | August 2021 | October 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17430171 | METHODS OF TREATMENT AND RELATED COMPOSITIONS | August 2021 | October 2022 | Allow | 14 | 1 | 0 | Yes | No |
| 17397217 | ANTIBODY-DRUG CONJUGATES AND USES THEREOF | August 2021 | December 2023 | Abandon | 29 | 0 | 1 | No | No |
| 17395366 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | August 2021 | September 2023 | Abandon | 25 | 0 | 0 | No | No |
| 17444511 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | August 2021 | July 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17383855 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | July 2021 | January 2024 | Allow | 29 | 1 | 1 | No | No |
| 17383892 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | July 2021 | January 2024 | Allow | 30 | 1 | 1 | No | No |
| 17383076 | Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use Thereof | July 2021 | April 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17381858 | METHODS FOR MODULATING AN IMMUNE RESPONSE | July 2021 | December 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17375793 | HER-2 Binding Antibodies | July 2021 | June 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17366512 | Inhibitory Immune Receptor Inhibition Methods and Compositions | July 2021 | March 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17358676 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | June 2021 | January 2024 | Allow | 30 | 1 | 1 | No | No |
| 17357410 | ANTI-TUMOR T CELL IMMUNITY INDUCED BY HIGH DOSE RADIATION | June 2021 | July 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17351963 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF THERAPEUTIC BIOLOGICS FOR TREATMENT OF DISEASE | June 2021 | April 2022 | Allow | 10 | 2 | 0 | Yes | No |
| 17350963 | MARKERS OF ACUTE MYELOID LEUKEMIA STEM CELLS | June 2021 | March 2022 | Allow | 9 | 1 | 0 | No | No |
| 17351014 | ANTIBODIES SPECIFIC TO MUC18 | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17336588 | THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132) | June 2021 | March 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17328364 | DISEASE-ASSOCIATED ANTIGENS AND METHODS OF USE THEREOF | May 2021 | September 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17328103 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | May 2021 | November 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17328465 | IDENTIFICATION, SELECTION AND USE OF HIGH CURATIVE POTENTIAL T CELL EPITOPES | May 2021 | September 2023 | Abandon | 27 | 0 | 1 | No | No |
| 17328116 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | May 2021 | April 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17327116 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | May 2021 | August 2023 | Allow | 27 | 1 | 1 | No | No |
| 17324148 | Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase | May 2021 | October 2024 | Allow | 41 | 3 | 1 | Yes | No |
| 17320782 | IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | May 2021 | September 2023 | Allow | 28 | 1 | 1 | No | No |
| 17317864 | ANTIBODY-STING AGONIST CONJUGATES AND THEIR USE IN IMMUNOTHERAPY | May 2021 | October 2021 | Allow | 6 | 1 | 0 | No | No |
| 17302687 | MANF as a Regulator of Immune System Function | May 2021 | July 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17291794 | SYSTEMS AND METHODS FOR TARGETING CANCER CELLS | May 2021 | June 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17290078 | STABLE PREPARATION COMPRISING ANTI-PCSK9 ANTIBODY | April 2021 | June 2025 | Abandon | 49 | 2 | 1 | Yes | No |
| 17238943 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | April 2021 | August 2023 | Allow | 27 | 1 | 1 | No | No |
| 17236709 | IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE | April 2021 | February 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17286748 | Targeting CLPTM1L for Treatment and Prevention of Cancer | April 2021 | June 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17226199 | CANCER THERAPY WITH AN ONCOLYTIC VIRUS COMBINED WITH A CHECKPOINT INHIBITOR | April 2021 | October 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17221854 | COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT | April 2021 | March 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17220799 | DEVELOPMENT OF DUAL WHOLE CELL-BASED VACCINE AGAINST PANCREATIC CANCER | April 2021 | April 2024 | Allow | 37 | 2 | 0 | No | No |
| 17204846 | METHODS OF CANCER TREATMENT USING ACTIVATED T CELLS | March 2021 | September 2021 | Allow | 6 | 0 | 1 | Yes | No |
| 17249762 | HISTOCHEMICAL AND CYTOCHEMICAL METHODS FOR DETECTING NTRK FUSION PROTEINS | March 2021 | April 2025 | Allow | 49 | 3 | 1 | Yes | No |
| 17193933 | CELL-PENETRATING ANTI-DNA ANTIBODIES AND USES THEREOF INHIBIT DNA REPAIR | March 2021 | May 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17193795 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | March 2021 | May 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17187468 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR | February 2021 | July 2021 | Allow | 4 | 1 | 0 | Yes | No |
| 17180064 | METHODS FOR MODULATING AN IMMUNE RESPONSE | February 2021 | June 2021 | Allow | 4 | 1 | 0 | Yes | No |
| 17267164 | COMPLEMENT FACTOR H AND Fc BINDING DOMAIN FUSION PROTEINS | February 2021 | March 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17161253 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER | January 2021 | April 2021 | Allow | 2 | 0 | 0 | No | No |
| 17157126 | ENDOPLASMIC RETICULUM STRESS AS A PREDICTIVE TOOL IN CANCER THERAPY AND A COMBINATION THERAPY FOR THE TREATMENT OF CANCER | January 2021 | July 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17153345 | METHODS AND USES FOR TREATING CANCER | January 2021 | July 2023 | Allow | 30 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner XIAO, YAN.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner XIAO, YAN works in Art Unit 1642 and has examined 817 patent applications in our dataset. With an allowance rate of 62.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner XIAO, YAN's allowance rate of 62.9% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by XIAO, YAN receive 1.76 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by XIAO, YAN is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +60.4% benefit to allowance rate for applications examined by XIAO, YAN. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 33.9% of applications are subsequently allowed. This success rate is in the 69% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 46.1% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 150.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 95.7% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 56% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.